Logotype for Dexcom Inc

Dexcom (DXCM) Q4 2021 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Dexcom Inc

Q4 2021 earnings summary

4 Nov, 2026

Executive summary

  • FY2021 revenue grew 27% to $2.448B as global CGM customer additions reached a record; year-end users estimated at 1.25M.

  • Gross margin expanded and cash resources remained strong, while operating income and net income declined YoY amid higher investment and a one-time Verily milestone charge.

Financial highlights

  • Revenue was $2,448.5M, up 27% YoY; gross profit rose 31% to $1,680.5M and gross margin increased to 68.6% from 66.4%.

  • Operating income fell 11% to $265.8M; net income fell 69% to $154.7M, reflecting higher expenses and the prior-year tax benefit from releasing a valuation allowance.

  • Basic EPS was $1.60 vs. $5.23; diluted EPS was $1.55 vs. $5.06.

  • Revenue growth was driven by higher disposable sensor volume from customer-base expansion, partly offset by channel mix and pricing; sensor and other revenue was 84% of sales vs. 81%.

Outlook and guidance

  • Prior-year non-GAAP gross and operating margin expectations were exceeded; 2022 priorities include G7 regulatory clearance and launch, broader access, and continued expansion of customer reach.

  • Significant capital spending is expected in the next year for Malaysia manufacturing build-out and Mesa capacity expansion; available liquidity is expected to cover operating and capital needs for at least 12 months.

  • Revenue typically runs lower in Q1 than Q4 because of U.S. insurance deductible resets and unfunded flexible spending accounts.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Dexcom